Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
Valero Energy Expands Venezuelan Crude Imports as U.S. Sanctions Ease 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
Bank of America CEO Brian Moynihan’s 2025 Compensation Rises 17% to $41 Million Amid Strong Profit Growth 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
Paramount Skydance Appoints Rene Augustine as SVP of Global Public Policy Amid Warner Bros Takeover Battle 
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks 
Lockheed Martin Secures $101M in U.S. Defense Contracts for AEGIS, F-35, and Missile Systems 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Sachem Head Boosts Warner Bros. Discovery Stake Amid Netflix Deal and Paramount Bid 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
EAST RUTHERFORD, N.J., Nov. 03, 2017 -- Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that Steven Klosk, President and Chief Executive Officer, will present at the Stephens Fall Investment Conference on November 8, 2017 at 10:00 a.m. EST in New York City.
The live audio webcast and slide presentation can be accessed from the Cambrex website at www.cambrex.com in the Investors section under “Webcasts & Presentations”, and a replay will be available for 90 days after the live event concludes.
About Cambrex
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis and controlled substances. For more information, please visit www.cambrex.com.
Contact:
Stephanie LaFiura
IR Associate
Tel: +201 804 3037
Email: [email protected]
